ContributorsPublishersAdvertisers

Durvalumab Plus Tremelimumab Combo Provides Significant Survival Benefit in First-Line Unresectable Hepatocellular Carcinoma

cancernetwork.com
 2021-10-15

Cover picture for the articlePatients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial. The addition of a high priming dose of tremelimumab (CP-675) to durvalumab (Imfinzi) in the first-line setting yielded a statistically significant and clinically meaningful overall survival (OS) benefit...

www.cancernetwork.com

Comments / 0

Comments / 0